SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: xbrent who wrote (328)5/20/1998 8:08:00 PM
From: Brett Fleischman  Respond to of 705
 
I don't think it is negative that there will not be a CNBC interview...most of the time they say something to the affect that the stock run-up is premature, alot of hurdles ahead of us, yadda, yadda...let it run on its own merits...the CEO said he doesn't want an artificial run-up, so he will let things happen as they happen.

Brett



To: xbrent who wrote (328)5/20/1998 8:12:00 PM
From: JEFF CHAPMAN  Read Replies (1) | Respond to of 705
 
The results were from Phase I, not phase II:

As reported, Chief Executive Alvin Glasky told Dow Jones
that AIT-082 produced memory improvements "with one
dose." The trials, which involved 60 patients, were in the
Phase I test period. Phase II tests for AIT-082 began earlier
this month, he added.

interactive.wsj.com!DI05/20++5099!BT05/14++5640!BT05/11++1866!BT04/08++5363!BT04/01++1376!BT04/01++1375!BT02/26++5572!&time=05/20+14:53


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News